143 related articles for article (PubMed ID: 32461962)
1. Sorafenib-Loaded Long-Circulating Nanoliposomes for Liver Cancer Therapy.
Ye H; Zhou L; Jin H; Chen Y; Cheng D; Jiang Y
Biomed Res Int; 2020; 2020():1351046. PubMed ID: 32461962
[TBL] [Abstract][Full Text] [Related]
2. Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer.
Wen Z; Feng Y; Hu Y; Lian L; Huang H; Guo L; Chen S; Yang Q; Zhang M; Wan L; Xu K; Degejirifu ; Yan X
Aging (Albany NY); 2021 Jan; 13(2):1872-1882. PubMed ID: 33440348
[TBL] [Abstract][Full Text] [Related]
3. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
5. Decreasing acute toxicity and suppressing colorectal carcinoma using Sorafenib-loaded nanoparticles.
Li N; Chen Y; Sun H; Huang T; Chen T; Jiang Y; Yang Q; Yan X; Wu M
Pharm Dev Technol; 2020 Jun; 25(5):556-565. PubMed ID: 31958240
[No Abstract] [Full Text] [Related]
6. PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure.
Mo L; Song JG; Lee H; Zhao M; Kim HY; Lee YJ; Ko HW; Han HK
Nanomedicine; 2018 Feb; 14(2):557-567. PubMed ID: 29248675
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
Liu Y; Feng L; Liu T; Zhang L; Yao Y; Yu D; Wang L; Zhang N
Nanoscale; 2014 Mar; 6(6):3231-42. PubMed ID: 24500240
[TBL] [Abstract][Full Text] [Related]
8. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M
Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482
[TBL] [Abstract][Full Text] [Related]
9. Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer.
Matthaiou EI; Barar J; Sandaltzopoulos R; Li C; Coukos G; Omidi Y
Int J Nanomedicine; 2014; 9():1855-70. PubMed ID: 24790428
[TBL] [Abstract][Full Text] [Related]
10. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced.
Song X; Wang J; Xu Y; Shao H; Gu J
Colloids Surf B Biointerfaces; 2019 Aug; 180():110-117. PubMed ID: 31030022
[TBL] [Abstract][Full Text] [Related]
11. Improved drug targeting to liver tumor by sorafenib-loaded folate-decorated bovine serum albumin nanoparticles.
Wang H; Sun S; Zhang Y; Wang J; Zhang S; Yao X; Chen L; Gao Z; Xie B
Drug Deliv; 2019 Dec; 26(1):89-97. PubMed ID: 30744448
[TBL] [Abstract][Full Text] [Related]
12. Nanolipid-loaded Preyssler polyoxometalate: Synthesis, characterization and invitro inhibitory effects on HepG2 tumor cells.
Razavi SF; Bamoharram FF; Hashemi T; Shahrokhabadi K; Davoodnia A
Toxicol In Vitro; 2020 Oct; 68():104917. PubMed ID: 32580012
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
Lin TsT; Gao DY; Liu YC; Sung YC; Wan D; Liu JY; Chiang T; Wang L; Chen Y
J Control Release; 2016 Jan; 221():62-70. PubMed ID: 26551344
[TBL] [Abstract][Full Text] [Related]
15. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
Tunki L; Kulhari H; Vadithe LN; Kuncha M; Bhargava S; Pooja D; Sistla R
Eur J Pharm Sci; 2019 Sep; 137():104978. PubMed ID: 31254645
[TBL] [Abstract][Full Text] [Related]
16. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.
Wang Z; Zhao K; Zhang Y; Duan X; Zhao Y
Pharm Res; 2019 Aug; 36(10):145. PubMed ID: 31396764
[TBL] [Abstract][Full Text] [Related]
17. Tumor RNA-loaded nanoliposomes increases the anti-tumor immune response in colorectal cancer.
Dai D; Yin Y; Hu Y; Lu Y; Zou H; Lu G; Wang Q; Lian J; Gao J; Shen X
Drug Deliv; 2021 Dec; 28(1):1548-1561. PubMed ID: 34286631
[TBL] [Abstract][Full Text] [Related]
18. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
Wu B; Li A; Zhang Y; Liu X; Zhou S; Gan H; Cai S; Liang Y; Tang X
Expert Opin Drug Deliv; 2020 Apr; 17(4):573-587. PubMed ID: 32056461
[No Abstract] [Full Text] [Related]
19. Cell-penetrating Peptide-modified Targeted Drug-loaded Phase-transformation Lipid Nanoparticles Combined with Low-intensity Focused Ultrasound for Precision Theranostics against Hepatocellular Carcinoma.
Zhao H; Wu M; Zhu L; Tian Y; Wu M; Li Y; Deng L; Jiang W; Shen W; Wang Z; Mei Z; Li P; Ran H; Zhou Z; Ren J
Theranostics; 2018; 8(7):1892-1910. PubMed ID: 29556363
[No Abstract] [Full Text] [Related]
20. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
